A study led by Drs. Kim Chi & Alex Wyatt demonstrated that metastatic castration-resistant prostate cancer patients with germline DNA repair defects respond poorly to androgen receptor-targeted therapy. However, biallelic gene loss was robustly detected in circulating tumor DNA, suggesting that this patient subset could be prioritized for therapies exploiting defective DNA repair using a liquid biopsy. Click here for the publication, "Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer" in the journal European Urology (March 2 issue, link opens in new window).
Click here to see a Prostate Cancer Canada video (YouTube) of Dr. Wyatt discussing the diagnostic significance of the article.